The contemporary concept of significant versus insignificant prostate cancer.

PubWeight™: 2.29‹?› | Rank: Top 2%

🔗 View Article (PMID 21601982)

Published in Eur Urol on May 17, 2011

Authors

Guillaume Ploussard1, Jonathan I Epstein, Rodolfo Montironi, Peter R Carroll, Manfred Wirth, Marc-Oliver Grimm, Anders S Bjartell, Francesco Montorsi, Stephen J Freedland, Andreas Erbersdobler, Theodorus H van der Kwast

Author Affiliations

1: Department of Urology, Saint-Louis Hospital, APHP, Paris, France. g.ploussard@gmail.com

Associated clinical trials:

To Investigate the Diagnostic Accuracy of Exosomal microRNA in Predicting the Aggressiveness of Prostate Cancer in Chinese Patients | NCT03911999

Articles citing this

Effect of soy protein isolate supplementation on biochemical recurrence of prostate cancer after radical prostatectomy: a randomized trial. JAMA (2013) 3.40

Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98

A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol (2014) 1.79

Magnetic resonance imaging for predicting prostate biopsy findings in patients considered for active surveillance of clinically low risk prostate cancer. J Urol (2012) 1.64

Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy. Urology (2012) 1.54

Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol (2015) 1.42

Prognostic DNA methylation markers for prostate cancer. Int J Mol Sci (2014) 1.05

Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard. Prostate Cancer Prostatic Dis (2013) 1.05

A biomedical engineering approach to mitigate the errors of prostate biopsy. Nat Rev Urol (2012) 1.02

Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol (2013) 1.00

Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol (2014) 0.92

How accurate is our prediction of biopsy outcome? PCA3-based nomograms in personalized diagnosis of prostate cancer. Cent European J Urol (2012) 0.90

MRI-Safe Robot for Endorectal Prostate Biopsy. IEEE ASME Trans Mechatron (2013) 0.90

Accuracy analysis in MRI-guided robotic prostate biopsy. Int J Comput Assist Radiol Surg (2013) 0.87

The cost-utility of open prostatectomy compared with active surveillance in early localised prostate cancer. BMC Health Serv Res (2014) 0.87

Performance of multiparametric magnetic resonance imaging in the evaluation and management of clinically low-risk prostate cancer. Urol Oncol (2013) 0.86

Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer. J Cancer Res Clin Oncol (2014) 0.84

The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance. Prostate Int (2014) 0.84

Prostate volume and biopsy tumor length are significant predictors for classical and redefined insignificant cancer on prostatectomy specimens in Japanese men with favorable pathologic features on biopsy. BMC Urol (2014) 0.83

Prostate MRI based on PI-RADS version 2: how we review and report. Cancer Imaging (2016) 0.83

Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy. Virchows Arch (2015) 0.82

Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer. World J Urol (2015) 0.82

Current status of active surveillance in prostate cancer. Investig Clin Urol (2016) 0.81

Detection rate of clinically insignificant prostate cancer increases with repeat prostate biopsies. Asian J Androl (2012) 0.81

Active surveillance for prostate cancer. Int J Urol (2015) 0.80

What kind of prostate cancers do we miss on multiparametric magnetic resonance imaging? Eur Radiol (2015) 0.80

Diffusion-weighted endorectal MR imaging at 3T for prostate cancer: correlation with tumor cell density and percentage Gleason pattern on whole mount pathology. Abdom Radiol (2016) 0.79

Preoperative prostate biopsy and multiparametric magnetic resonance imaging: reliability in detecting prostate cancer. Int Braz J Urol (2015) 0.79

Can microfocal prostate cancer be regarded as low-risk prostate cancer? Prostate Int (2013) 0.79

The role of MRI in prostate cancer active surveillance. Biomed Res Int (2014) 0.79

Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL. Yonsei Med J (2016) 0.79

Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer. Virchows Arch (2016) 0.78

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies. World J Urol (2016) 0.78

Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis (2016) 0.78

Are more low-risk prostate cancers detected by repeated biopsy? A retrospective pilot study. Korean J Urol (2013) 0.78

Insignificant disease among men with intermediate-risk prostate cancer. World J Urol (2014) 0.77

Will Multi-Parametric Magnetic Resonance Imaging be the Future Tool to Detect Clinically Significant Prostate Cancer? Front Oncol (2014) 0.77

Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up. Virchows Arch (2014) 0.76

Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. Insights Imaging (2016) 0.76

Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. Prostate (2016) 0.76

Men under the age of 55 years with screen detected prostate cancer do not have less significant disease compared to older men in a population of patients in Australia. BMC Urol (2015) 0.75

Radical prostatectomy specimens - a voice against focal therapy. Cent European J Urol (2014) 0.75

CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS. Trans Am Clin Climatol Assoc (2016) 0.75

Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview. Int Sch Res Notices (2014) 0.75

Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate Int (2014) 0.75

Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer. BJU Int (2014) 0.75

The prostate cancer prevention trial risk calculator 2.0 performs equally for standard biopsy and MRI/US fusion-guided biopsy. Prostate Cancer Prostatic Dis (2017) 0.75

mp-MRI Prostate Characterised PIRADS 3 Lesions are Associated with a Low Risk of Clinically Significant Prostate Cancer - A Retrospective Review of 92 Biopsied PIRADS 3 Lesions. Curr Urol (2015) 0.75

Clinical significance of single microscopic focus of adenocarcinoma at prostate biopsy. Prostate Int (2015) 0.75

Are hypoechoic lesions on transrectal ultrasonography a marker for clinically significant prostate cancer? Korean J Urol (2013) 0.75

Multi-slice-to-volume registration for MRI-guided transperineal prostate biopsy. Int J Comput Assist Radiol Surg (2014) 0.75

Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis. Int J Clin Exp Med (2015) 0.75

Biopsy Perineural Invasion in Prostate Cancer Patients Who are Candidates for Active Surveillance by Strict and Expanded Criteria. Urology (2016) 0.75

Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy. Prostate Cancer Prostatic Dis (2017) 0.75

Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men. Radiology (2017) 0.75

Comparison of clinical outcomes between upgraded pathologic Gleason score 3 + 4 and non-upgraded 3 + 4 prostate cancer among patients who are candidates for active surveillance. World J Urol (2015) 0.75

Differentiation of prostate cancer lesions with high and with low Gleason score by diffusion-weighted MRI. Eur Radiol (2016) 0.75

Pathological outcomes of Japanese men eligible for active surveillance after radical prostatectomy. Int J Clin Oncol (2013) 0.75

PI-RADS version 2: quantitative analysis aids reliable interpretation of diffusion-weighted imaging for prostate cancer. Eur Radiol (2016) 0.75

[PI-RADS 2.0 for Prostate MRI]. Radiologe (2017) 0.75

Articles by these authors

Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78

Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14

Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93

Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst (2007) 5.69

Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62

Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27

Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer (2010) 5.22

The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87

2004 WHO classification of the renal tumors of the adults. Eur Urol (2006) 4.85

National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst (2003) 4.81

Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol (2004) 4.66

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2007) 4.64

Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58

Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst (2003) 4.42

The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol (2005) 4.40

A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37

Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24

Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17

Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol (2010) 4.11

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol (2013) 4.04

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology (2007) 4.02

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol (2010) 3.95

Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93

Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92

The changing face of prostate cancer. J Clin Oncol (2005) 3.84

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol (2010) 3.79

EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74

The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68

Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol (2008) 3.64

MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol (2011) 3.57

Increased telomerase activity and comprehensive lifestyle changes: a pilot study. Lancet Oncol (2008) 3.57

Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol (2010) 3.55

Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol (2012) 3.53

Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41

Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31

Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26

Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25

Assessing the impact of ischaemia time during partial nephrectomy. Eur Urol (2009) 3.18

Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18

A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18

Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17

Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomes. Cancer (2008) 3.14

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol (2007) 3.14

Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14

Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12

ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08

A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07

Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort. Eur Urol (2011) 3.07

The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06

Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes? Am J Surg Pathol (2012) 3.05

Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03

Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol (2009) 3.01

Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01

Pathological and molecular aspects of prostate cancer. Lancet (2003) 2.98

Insignificant prostate cancer and active surveillance: from definition to clinical implications. Eur Urol (2009) 2.97

Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst (2006) 2.96

Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95

The use of morphological characteristics and texture analysis in the identification of tissue composition in prostatic neoplasia. Hum Pathol (2004) 2.94

Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol (2003) 2.93

Active surveillance for prostate cancer: progress and promise. J Clin Oncol (2011) 2.93

Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91

Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer (2010) 2.90

Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol (2009) 2.88

Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88

Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88

The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst (2009) 2.84

Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol (2012) 2.84

Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83

Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol (2010) 2.82

The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer (2011) 2.78

Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. Eur Urol (2012) 2.77

Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol (2003) 2.77

An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77

Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76

Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76

Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74

Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. Eur Urol (2011) 2.74

Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72

Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72

The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70

Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol (2007) 2.69

Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69

Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol (2002) 2.68

A plea for integrating laparoscopy and robotic surgery in everyday urology: the rules of the game. Eur Urol (2007) 2.68

Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66